All updated as on -
The size of the world market for in vitro diagnostics was estimated to be $71,496.19 million in 2022, and it is anticipated to increase to $106,914.19 million by 2030, rising at a CAGR of 6.08% from 2023 to 2030.
For the purpose of diagnosing illnesses, disorders, and infections, in vitro diagnostics (IVD) refers to the reagents, tools, and software used to analyze specimens taken from the human body, such as blood, urine, stool, tissues, and other physiological fluids. There are also other IVD device types that employ various techniques, including immunodiagnostics, tissue diagnostics, hematological, and molecular diagnostics. Devices are used in specialized medical facilities to carry out diagnostics since the application and management of the IVD market require technical competence.
For instance, IVD products are used in hospitals, standalone labs, and point-of-care testing centers. To enable smooth operations, the in vitro testing approach requires the use of a number of reagents as well as software. Additionally, a variety of medical conditions, such as infectious diseases, diabetes, cancer, oncology, cardiac disorders, autoimmune disorders, nephrology, and HIV/AIDS, are diagnosed using in vitro diagnostics.
The rise in the prevalence of chronic and infectious diseases is a primary factor driving the IVD market's expansion. Chronic diseases like diabetes, cancer, cardiovascular disease, and tuberculosis are becoming more common in the contemporary business environment. Additionally, the number of people with infectious disorders as gastrointestinal, respiratory, and STDs (sexually transmitted diseases) has also increased. The market for IVDs is driven by the demand for diagnostic tools, which is anticipated to rise as these diseases become more prevalent.
IVD uses a variety of tests and methods to identify a wide range of illnesses. Different market segments were affected by the COVID-19 pandemic in both positive and bad ways, however the increasing use of molecular diagnostics offset the negative effects of other market segments, creating a positive influence on the market throughout the pandemic. SARS-CoV-2 virus diagnosis was done using molecular diagnostic methods. Additionally, there was a rise in the need for test kits and other supplies for COVID-19 hospital patients who were monitoring their blood sugar and troponin levels. The need for point-of-care testing based on molecular methods and serology has greatly expanded as a result. Market participants saw a huge increase in the sales of molecular and point-of-care tests, which significantly increased their revenues. For instance, Abbott's molecular diagnostics business saw revenue increase by over 225% in 2020 compared to 2019.
Since the usage and management of the IVD market demand technical knowledge, diagnoses are performed with the aid of devices in specialized medical facilities. In vitro diagnostics (IVD) describes the chemicals, equipment, and software used to examine bodily specimens such as blood, urine, stool, tissues, and other physiological fluids in order to identify diseases, abnormalities, and infections. Other IVD device types use a variety of methods, such as molecular, tissue, haematological, and immunodiagnostic tests.
Medical device businesses are diligently creating technologically cutting-edge diagnostic tools due to the rising burden of diseases. To obtain accurate real-time data, hospitals and laboratories have shown a rising preference for point-of-care testing equipment. Point-of-Care (PoC) testing is carried out close to the patient, often only a small amount of blood, and offers test findings more quickly during clinical decision-making, allowing doctors to decide on a course of therapy before waiting for results from a central laboratory. This element will probably lead to an increase in the need for point-of-care testing equipment, which will then raise the demand for in-vitro diagnostics equipment.
The in vitro diagnostics market is divided into segments in the report based on product & service, technique, application, end user, and region. Reagents, instruments, and services & software make up the market's product and service segments. It is divided into immunodiagnostics, hematological, molecular diagnostics, tissue diagnostics, clinical chemistry, and other categories based on technique. Additionally, the immunodiagnostics section is further broken down into other categories including western blot, radioimmunoassay (RIA), enzyme-linked immunospot (ELISPOT), fast tests, and enzyme-linked immunosorbent assay (ELISA). The ELSIA market is additionally split into the chemiluminescence immunoassay (CLIA), fluorescence immunoassay (FIA), and colorimetric immunoassay (CI) subsectors. Similar categories include polymerize chain reaction (PCR), isothermal nucleic acid amplification technology (INAAT), hybridization, DNA diagnostics, microarray, and others under the molecular diagnostics category.
Report Coverage
Global In Vitro Diagnostics (IVD) research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global In Vitro Diagnostics (IVD) report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and In Vitro Diagnostics (IVD) competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key In Vitro Diagnostics (IVD) market players and analyses their core competencies in each global market sub-segments.
Key Points Covered in the Report
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global In Vitro Diagnostics (IVD) market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, In Vitro Diagnostics (IVD) market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
Abbott Laboratories, QIAGEN N.V., bioMérieux SA, Bio-Rad Laboratories, Inc., Hoffmann-La Roche AG, Sysmex Corporation, Thermo Fisher Scientific, Inc., Becton, Dickinson and Company, Danaher Corporation (Beckman Coulter, Inc.), Siemens (Germany), General Electric (U.S.), Koninklijke Philips N.V. (Netherlands), CANON MEDICAL SYSTEMS CORPORATION (Japan), Hitachi Ltd. (Japan), FUJIFILM Holdings Corporation (Japan), Carestream Health (U.S.), Konica Minolta Business Solutions India Private Limited. (Japan), Hologic, Inc. (U.S.), SouthwestMedical (U.K.), TOSHIBA CORPORATION (Japan), Sanrad Medical Systems Private Limited (India), ONEX Corporation (Canada), Shimadzu Corporation (Japan), ESAOTE SPA (Italy)
Primary Target Market
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2030. INFINITIVE DATA EXPERT has segmented the global In Vitro Diagnostics (IVD) market based on the below-mentioned segments:
Global In Vitro Diagnostics (IVD) Market, By Product And Services
Reagents
Instruments
Software And Services
Global In Vitro Diagnostics (IVD) market, By Application
Infectious Diseases
Cancer
Cardiac Diseases
Immune System Disorders
Nephrological Diseases
Gastrointestinal Diseases
Others
Global In Vitro Diagnostics (IVD) Market, By End User
Standalone Laboratories
Hospitals
Academic And Medical Schools
Point Of Care
Others
Global In Vitro Diagnostics (IVD) market, Regional Analysis
For the purpose of diagnosing illnesses, disorders, and infections, in vitro diagnostics (IVD) refers to the reagents, tools, and software used to analyze specimens taken from the human body, such as blood, urine, stool, tissues, and other physiological fluids. There are also other IVD device types that employ various techniques, including immunodiagnostics, tissue diagnostics, hematological, and molecular diagnostics. Devices are used in specialized medical facilities to carry out diagnostics since the application and management of the IVD market require technical competence.
For instance, IVD products are used in hospitals, standalone labs, and point-of-care testing centers. To enable smooth operations, the in vitro testing approach requires the use of a number of reagents as well as software. Additionally, a variety of medical conditions, such as infectious diseases, diabetes, cancer, oncology, cardiac disorders, autoimmune disorders, nephrology, and HIV/AIDS, are diagnosed using in vitro diagnostics.
The rise in the prevalence of chronic and infectious diseases is a primary factor driving the IVD market's expansion. Chronic diseases like diabetes, cancer, cardiovascular disease, and tuberculosis are becoming more common in the contemporary business environment. Additionally, the number of people with infectious disorders as gastrointestinal, respiratory, and STDs (sexually transmitted diseases) has also increased. The market for IVDs is driven by the demand for diagnostic tools, which is anticipated to rise as these diseases become more prevalent.
IVD uses a variety of tests and methods to identify a wide range of illnesses. Different market segments were affected by the COVID-19 pandemic in both positive and bad ways, however the increasing use of molecular diagnostics offset the negative effects of other market segments, creating a positive influence on the market throughout the pandemic. SARS-CoV-2 virus diagnosis was done using molecular diagnostic methods. Additionally, there was a rise in the need for test kits and other supplies for COVID-19 hospital patients who were monitoring their blood sugar and troponin levels. The need for point-of-care testing based on molecular methods and serology has greatly expanded as a result. Market participants saw a huge increase in the sales of molecular and point-of-care tests, which significantly increased their revenues. For instance, Abbott's molecular diagnostics business saw revenue increase by over 225% in 2020 compared to 2019.
Since the usage and management of the IVD market demand technical knowledge, diagnoses are performed with the aid of devices in specialized medical facilities. In vitro diagnostics (IVD) describes the chemicals, equipment, and software used to examine bodily specimens such as blood, urine, stool, tissues, and other physiological fluids in order to identify diseases, abnormalities, and infections. Other IVD device types use a variety of methods, such as molecular, tissue, haematological, and immunodiagnostic tests.
Medical device businesses are diligently creating technologically cutting-edge diagnostic tools due to the rising burden of diseases. To obtain accurate real-time data, hospitals and laboratories have shown a rising preference for point-of-care testing equipment. Point-of-Care (PoC) testing is carried out close to the patient, often only a small amount of blood, and offers test findings more quickly during clinical decision-making, allowing doctors to decide on a course of therapy before waiting for results from a central laboratory. This element will probably lead to an increase in the need for point-of-care testing equipment, which will then raise the demand for in-vitro diagnostics equipment.
The in vitro diagnostics market is divided into segments in the report based on product & service, technique, application, end user, and region. Reagents, instruments, and services & software make up the market's product and service segments. It is divided into immunodiagnostics, hematological, molecular diagnostics, tissue diagnostics, clinical chemistry, and other categories based on technique. Additionally, the immunodiagnostics section is further broken down into other categories including western blot, radioimmunoassay (RIA), enzyme-linked immunospot (ELISPOT), fast tests, and enzyme-linked immunosorbent assay (ELISA). The ELSIA market is additionally split into the chemiluminescence immunoassay (CLIA), fluorescence immunoassay (FIA), and colorimetric immunoassay (CI) subsectors. Similar categories include polymerize chain reaction (PCR), isothermal nucleic acid amplification technology (INAAT), hybridization, DNA diagnostics, microarray, and others under the molecular diagnostics category.
Report Coverage
Global In Vitro Diagnostics (IVD) research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global In Vitro Diagnostics (IVD) report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and In Vitro Diagnostics (IVD) competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key In Vitro Diagnostics (IVD) market players and analyses their core competencies in each global market sub-segments.
| REPORT ATTRIBUTES | DETAILS |
|---|---|
| Study Period | 2017-2030 |
| Base Year | 2022 |
| Forecast Period | 2022-2030 |
| Historical Period | 2017-2021 |
| Unit | Value (USD Billion) |
| Key Companies Profiled | Abbott Laboratories, QIAGEN N.V., bioMérieux SA, Bio-Rad Laboratories, Inc., Hoffmann-La Roche AG, Sysmex Corporation, Thermo Fisher Scientific, Inc., Becton, Dickinson and Company, Danaher Corporation (Beckman Coulter, Inc.), Siemens (Germany), General Electric (U.S.), Koninklijke Philips N.V. (Netherlands), CANON MEDICAL SYSTEMS CORPORATION (Japan), Hitachi Ltd. (Japan), FUJIFILM Holdings Corporation (Japan), Carestream Health (U.S.), Konica Minolta Business Solutions India Private Limited. (Japan), Hologic, Inc. (U.S.), SouthwestMedical (U.K.), TOSHIBA CORPORATION (Japan), Sanrad Medical Systems Private Limited (India), ONEX Corporation (Canada), Shimadzu Corporation (Japan), ESAOTE SPA (Italy) |
| Segments Covered | • By Product |
| Customization Scope | Free report customization (equivalent to up to 3 analyst working days) with purchase. Addition or alteration to country, regional & segment scope |
Key Points Covered in the Report
- Market Revenue of In Vitro Diagnostics (IVD) Market from 2021 to 2030.
- Market Forecast for In Vitro Diagnostics (IVD) Market from 2021 to 2030.
- Regional Market Share and Revenue from 2021 to 2030.
- Country Market share within region from 2021 to 2030.
- Key Type and Application Revenue and forecast.
- Company Market Share Analysis, In Vitro Diagnostics (IVD) competitive scenario, ranking, and detailed company
profiles. - Market driver, restraints, and detailed COVID-19 impact on In Vitro Diagnostics (IVD)
Market
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global In Vitro Diagnostics (IVD) market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, In Vitro Diagnostics (IVD) market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
Abbott Laboratories, QIAGEN N.V., bioMérieux SA, Bio-Rad Laboratories, Inc., Hoffmann-La Roche AG, Sysmex Corporation, Thermo Fisher Scientific, Inc., Becton, Dickinson and Company, Danaher Corporation (Beckman Coulter, Inc.), Siemens (Germany), General Electric (U.S.), Koninklijke Philips N.V. (Netherlands), CANON MEDICAL SYSTEMS CORPORATION (Japan), Hitachi Ltd. (Japan), FUJIFILM Holdings Corporation (Japan), Carestream Health (U.S.), Konica Minolta Business Solutions India Private Limited. (Japan), Hologic, Inc. (U.S.), SouthwestMedical (U.K.), TOSHIBA CORPORATION (Japan), Sanrad Medical Systems Private Limited (India), ONEX Corporation (Canada), Shimadzu Corporation (Japan), ESAOTE SPA (Italy)
Primary Target Market
- Market Players of In Vitro Diagnostics (IVD)
- Investors
- End-users
- Government Authorities
- Consulting And Research Firm
- Venture capitalists
- Third-party knowledge providers
- Value-Added Resellers (VARs)
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2030. INFINITIVE DATA EXPERT has segmented the global In Vitro Diagnostics (IVD) market based on the below-mentioned segments:
Global In Vitro Diagnostics (IVD) Market, By Product And Services
Reagents
Instruments
Software And Services
Global In Vitro Diagnostics (IVD) market, By Application
Infectious Diseases
Cancer
Cardiac Diseases
Immune System Disorders
Nephrological Diseases
Gastrointestinal Diseases
Others
Global In Vitro Diagnostics (IVD) Market, By End User
Standalone Laboratories
Hospitals
Academic And Medical Schools
Point Of Care
Others
Global In Vitro Diagnostics (IVD) market, Regional Analysis
- Europe: Germany, Uk, France, Italy, Spain, Russia, Rest of Europe
- The Asia Pacific: China,Japan,India,South Korea,Australia,Rest of Asia Pacific
- South America: Brazil, Argentina, Rest of South America
- Middle East & Africa: UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa
About This Research
You will get in-depth and extensive in vitro diagnostics ivd market market research and competitor analysis for your business to help you develop more profound insights into the in vitro diagnostics ivd market Market.
Through INFINITIVE Data Expert is a professional Market Research services, I will identify the in vitro diagnostics ivd market market size, demand & opportunities, growth rate, and target audience with a comprehensive analysis of your competitors.